Sage Therapeutics (SAGE) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition adds ZURZUVAE, the only FDA-approved oral treatment for postpartum depression, expanding the CNS and OB-GYN portfolio and diversifying revenue streams.

• Strengthens presence in neuropsychiatric conditions and leverages CNS discovery platform and expertise.

• Accelerates mid- to long-term revenue and cash flow growth, complementing existing growth products.

• Aligns with strategy to build a leading CNS position and expand into adjacent therapeutic areas.

• Zurzuvae's strong launch and momentum provide a new growth catalyst and long-term growth driver.

Financial terms and conditions

• Offer price is $8.50 per share in cash at closing, plus up to $3.50 per share in contingent value rights tied to sales and regulatory milestones, totaling up to $12.00 per share.

• Equity value at closing is $561 million, with total potential value up to $795 million.

• Financing will be through cash on hand.

• CVR milestones include U.S. net sales targets for ZURZUVAE and first commercial sale in Japan after regulatory approval.

Synergies and expected cost savings

• Up to $200 million in annualized synergies expected, primarily from SG&A and R&D rationalization.

• Acquisition expected to be significantly accretive in 2026.

• Most commercial infrastructure for Zurzuvae will be retained to sustain launch momentum.